No one can object to businesses with larger turnover getting volume discounts and incentives. The deals are reasonably transparent as presented to pharmacies by generic companies. Price disclosure policy and improved codes of practice amongst generic companies and trade practices oversight has help this. It is perhaps the advantageous settlement terms that were before and probably still are the main point of discontent. Obviously the terms are confidential but can include the likes of extended credit, settlement discounts and rebates etc.
The preferential terms have in part help fund the CW expansion much to the discontent of Sigma's group pharmacies.
No one can object to businesses with larger turnover getting...
-
- There are more pages in this discussion • 63 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SIG (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.95 |
Change
0.085(2.97%) |
Mkt cap ! $2.300B | |||
| Open | High | Low | Value | Volume |
| $2.87 | $2.95 | $2.85 | $12.16M | 4.179M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 83157 | $2.94 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.95 | 86224 | 44 |
View Market Depth
| Last trade - 14.40pm 03/12/2024 (20 minute delay) ? |
| SIG (ASX) Chart |
